Morphological features of recovery in model rats liver cirrhosis induced by CCl4 after transplantation of mesenchymal stem cells from human umbillical cord

  • P. O. Pikus
  • S. Yu. Rymar
  • N. S. Shuvalova
  • P. V. Butschek


Aim. To study the process of recovery of rat liver in a model of cirrhosis, which was induced by intraperitoneal
injection of CCl4, after transplantation human umbilical cord MSCs. Today in the world as an alternative to liver transplantation is offered cell therapy, which leads to the recovery of organ’s functions through the injection of MSCs. The key role of MSCs in the development of fibrosis and its final stage - liver cirrhosis is the inhibitory effect on the proliferation of the extracellular matrix. Methods. The methods of histology and morphometry were used in the work. Results. It was found, that 13 weeks after CCl4 induction, the amount of collagen increased 7 times, atrophic, sclerotic changes in the architectonics of rat liver and functional disorders of hepatocytes were observed. After transplantation of human umbilical cord MSCs - 6-7x106 cells / kg body weight of the animal, was shown that after 3 weeks the rate of collagen accumulation decreased and after 13 weeks the amount of ECMs and other morphometric indexes almost corresponded to the negative control. Conclusions. Studies have shown that transplantation MSCs from human umbilical cord leads to almost complete regeneration of the rat liver which was caused by experimental liver cirrhosis with intraperitoneal injection of CCl4.

Keywords: human umbilical cord MSCs, extracellular matrix, hepatocytes.


Chepelevska L.A., Dziuba O., Karamzina A. Suchasni problemy smertnosti naselennia Ukrainy vid khvorob orhaniv travlennia. Zdorov'ia naselennia: tendentsii ta prohnozy. 2015. Vol. 33 (1). P. 21-27. [in Ukrainian]

Ovdin O. Napriamy derzhavnoi polityky shchodo znyzhennia smertnosti naselennia Ukrainy. Derzhavne upravlinnia ta mistseve samovriaduvannia. 2013. Vol. 4 (19). P. 97-107. [in Ukrainian]

Owen А. Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt? American Journal of Physiology - Gastrointestinal and Liver Physiology Published. 2015. Vol. 309. Р. 23-29. doi: 10.1152/ajpgi.00036.2015

Squillaro T. Clinical Trials With Mesenchymal Stem Cells. An Update. Cell Transplant. 2016. Vol. 25, No. 5. P. 29-48. doi: 10.3727/096368915X689622

Radzikowski C. Protection of animal research subjects. Sci Eng Ethics. 2006. Vol. 12. P. 103-110. doi: 10.1007/s11948-006-0010-2

Luque J. Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. The American Society for Pharmacology and Experimental Therapeutics. 2008. Vol. 324. P. 10-23. doi: 10.1124/jpet.107.131896

Layfield L. Accuracy and Reproducibility of Nuclear/Cytoplasmic Ratio Assessments in Urinary Cytology Specimens. J. Diagnostic Cytopathology. 2017. Vol. 45. P. 107-112. doi: 10.1002/dc.23639

Bedossa P. Liver extracellular matrix in health and disease. J. Pathol. 2003. Vol. 200. P. 504-515. doi: 10.1002/path.1397

Padaki Rao N. Nodule in Liver: Investigations, Differential Diagnosis and Follow-up. J Clin Exp Hepatol. 2014. Vol. 23. P. 57-62. doi: 10.1016/j.jceh.2014.06.010

Lee J. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-b. Chem. Biol. Interact. 2014. Vol. 224. P. 58-67. doi: 10.1016/j.cbi.2014.10.005

Meyer D. Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun. 1990. Vol. 171. Р. 1122-1129. doi: 10.1016/0006-291X(90)90801-S

Constandinou C., Henderson N., Iredale J.P. Modeling liver fibrosis in rodents. Methods Mol Med. 2005. Vol. 117. P. 237-250. doi: 10.1385/1-59259-940-0:237